XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. We develop innovative  approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. and XAV19, its anti-COVID treatment for patients with moderate disease. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.